Stryker Corporation 10-Q Summary: Period Ended June 30, 2003
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2003, and the six-month period ended on that date. Stryker Corporation operates in two primary reportable segments: Orthopaedic Implants and MedSurg Equipment. The company also reports results for Physical Therapy Services and corporate administration under "Other."
Key Financial Metrics
Revenue and Profit (Six Months Ended June 30, 2003):
- Net Sales: $1,738.6 million (21% increase vs. prior year).
- Gross Profit: $1,110.9 million (63.9% margin).
- Net Earnings: $211.6 million (12.2% margin).
- Diluted EPS: $1.04 (27% increase vs. prior year).
Cash Flow and Liquidity:
- Cash from Operations: $225.3 million for the six-month period.
- Cash and Equivalents: $47.1 million as of June 30, 2003.
- Working Capital: $570.7 million (increase of $126.9 million from year-end 2002).
- Debt: Total outstanding borrowings were $365.4 million. Current maturities of long-term debt were $6.5 million.
Material Changes vs. Prior Period
Revenue Growth Drivers: Sales growth was driven by a 12% increase in unit volume and product mix, 5% from favorable foreign currency exchange rates, 2% from price increases, and 2% from acquisitions. International sales grew 27%, while domestic sales grew 18%.
Expense Trends:
- R&D Expenses: Increased 30% to $88.1 million due to new product launches.
- Selling, General & Administrative (SG&A): Increased 21% to $685.9 million, driven by higher sales commissions and a $7.4 million increase in insurance costs due to the establishment of a captive insurance company.
- Interest Expense: Declined to $13.4 million from $20.6 million due to lower debt balances and interest rates.
Segment Performance: Orthopaedic Implants sales increased 25% to $1,013.0 million. MedSurg Equipment sales increased 17% to $617.0 million.
Outlook, Risks, and Unusual Items
Management Commentary: Management attributes the increase in cost of sales percentage in the second quarter to redundant costs from facility transitions and product obsolescence from new launches. The effective income tax rate decreased to 31.0% from 33.0% due to increased manufacturing in lower tax jurisdictions.
Unusual Items and Contingencies:
- Acquisition Integration: The company finalized the purchase price allocation for the Surgical Dynamics Inc. (SDI) acquisition, recording additional purchase liabilities of $3.6 million for severance and contractual obligations.
- Insurance: The company established a wholly-owned captive insurance company in January 2003 to manage self-insured retention limits for product liability claims.
- Foreign Currency: A strengthening of foreign currencies resulted in an $83.0 million translation gain, eliminating a previously recorded cumulative loss.
Risks: Forward-looking statements are subject to risks including regulatory cost-containment measures, changes in third-party reimbursement levels, product liability claims, and foreign exchange fluctuations.
Investor Verification Checklist
- Verify the sustainability of the 27% international sales growth, noting the significant impact of favorable foreign currency exchange rates ($76.0 million impact in the first half).
- Monitor the impact of the new captive insurance company on future SG&A expenses and product liability reserves.
- Review the integration progress of the SDI acquisition and the associated $3.6 million in recorded liabilities.
- Assess the company's debt repayment strategy, noting the reduction of total borrowings by $136.3 million in the first half of 2003.
- Confirm the timeline for the amortization of the $84.5 million allocated to patent licensing agreements from the SDI acquisition.